"Fortune" featured in the top 500 pharmaceutical business
How strong is the growth momentum of Chinese pharmaceutical commercial companies? The "2011 China Top 500 Ranking" published recently by Fortune magazine (Chinese version) has given people a better un
How strong is the growth momentum of Chinese pharmaceutical commercial companies? The "2011 China Top 500 Ranking" published recently by Fortune magazine (Chinese version) has given people a better understanding: Kyushu Tong Medicine Group Co., Ltd., which broke into the list for the first time, has an annual income of 21.252 billion yuan. The net profit of 353 million yuan entered the 161th place.
The “Fortune” list shows that in 2011, there were 15 pharmaceutical companies short-listed, an increase of 2 compared to 2010; in addition to Kyushu Link, there were also Sanpu Pharmaceuticals, the newly-listed pharmaceutical company, which ranked 297th.
Business occupies half of medicine
Judging from the characteristics of short-listed pharmaceutical companies, industry analysts generally believe that because of the listing, Kyushu Express has only entered the Fortune List for the first time this year, and it is worth mentioning that commercial companies not only occupy half of the pharmaceutical companies in the list, the industry The top five are also divided by commercial companies and their development momentum is even better than that of industrial companies.
The “Fortune” list shows that for two consecutive years, the leading domestic pharmaceutical business leading Sinopharm Co., Ltd. has been on the list, ranking the 48th in both years and ranking first in the pharmaceutical industry. Although Sinopharm's ranking did not increase this year, both its annual sales revenue and net profit have increased significantly. According to the 2011 list, Sinopharm has sales revenue of 69.234 billion yuan and net profit of 1.209 billion yuan, a year-on-year increase of more than 47% and 42% respectively.
The ranking of Shanghai Pharmaceutical Group Co., Ltd., which ranks second in the list of pharmaceutical companies, rose from 136th in 2010 to 99th in 2011, a rise of 37 places. Shanghai Pharmaceutical Group's sales revenue was 37.411 billion yuan and net profit was 1.368 billion yuan. The growth in the previous period was nearly double the year-on-year increase, and the latter was more than six times higher than the same period last year. Nanjing Pharmaceutical Co., Ltd., ranked No. 4 among pharmaceutical companies, rose from No. 212 in 2010 to No. 174 in 2011, a total of 38 places. Nanjing Pharmaceutical's sales revenue was 15.338 billion yuan and net profit was 9 million yuan. Although its net profit declined, its sales volume increased by more than 9% year-on-year.
In addition, commercial companies such as Shenzhen Accord Pharmaceutical Co., Ltd., Huadong Medicine Co., Ltd. and other commercial companies have secured Fortune 500. Although the two companies' rankings have declined compared to 2010, both sales scale and net profit have varying degrees. growth of.
Policies and capital are strongly promoted
The industry generally believes that the size of the leading pharmaceutical and pharmaceutical business has grown rapidly in recent years, and is closely related to policy orientation and corporate strategy.
In recent years, with the further advancement of the new medical reform, the enormous “cake” of the Chinese pharmaceutical market, which amounts to hundreds of billions of yuan each year, has attracted companies from all walks of life. After the Sinopharm Group’s H-shares were listed and financed, a series of mergers and acquisitions was launched, and the sales scale quickly expanded. The exponential expansion of Shanghai Pharmaceuticals Group also benefited from mergers and acquisitions integration. The new drug has gathered the core medical assets and business of the two major groups of Shanghai Pharmaceutical and Shanghai Pharmaceutical Co., Ltd. and has become the leading comprehensive pharmaceutical company with the largest value in the A stock market and covering the whole industry chain of the pharmaceutical industry. The number one business leader is advancing on the capital road, while at the same time stimulating the nerves of the private pharmaceutical business; Kyushu Express accelerated its time to market and got what it wanted. Subsequent mergers and acquisitions are also pleasing to the wind, and they have become wealthy.
When China entered the WTO 10 years ago, pharmaceutical commercial companies faced unprecedented challenges. At that time, commercial companies that lacked market competition were lacking in service awareness due to long-term monopolies and were not willing to become bigger and stronger. According to the statistics of the former State Economic and Trade Commission, there were 17,000 companies engaged in the wholesale of pharmaceutical products in the country, but only 3 to 6 companies with annual sales exceeding 5 billion yuan, and more than 10 companies exceeding 1 billion yuan. After nearly a decade of baptism, although some of these companies are now able to change, the concentration process of commercial companies lags far behind that of industry, and there are still more than 10,000 commercial companies.
“The big screen for accelerating the concentration of the pharmaceutical and pharmaceutical industry has only just begun.” Some people in the industry believe that since the Ministry of Commerce took over the circulation of pharmaceuticals, increasing the concentration of the industry and reducing the circulation of pharmaceuticals has become the main reason for the government to reduce the high drug prices. means. In the “Outline of the National Pharmaceutical Distribution Industry Development Plan (2011-2015)” recently announced by the Ministry of Commerce, solving the problem of low concentration of the industry in the pharmaceutical distribution industry and developing modern pharmaceutical logistics are important tasks for the development of the national pharmaceutical distribution industry in the next five years. .
“The pharmaceutical distribution industry is affiliated with pharmaceutical manufacturing companies, and is affiliated with medical institutions and patients at the same time. This is the key link in the entire pharmaceutical supply chain system.” Chang Xiaocun, Director of the Department of Market Order of the Ministry of Commerce, recently extended the demonstration of pharmaceutical logistics services. This view published at the project site indicates that large commercial enterprises will leap to a new level once they break through the bottleneck of modern pharmaceutical logistics informatization.
“The top three US pharmaceutical distribution companies account for more than 95% of the entire pharmaceutical market, while the top 3 Chinese companies only account for about 20%.” The industry believes that in the future under the guidance of the policy, large-scale pharmaceutical business will expand faster , The increase in industry concentration will bring "big reshuffle" action.